Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.64 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.57 |
| ▸ | KCNJ1 | P48048 | 4/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.56 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.53 |
| ▸ | IDO1 | P14902 | 2/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3292782 | 0.86 | TSHR (0.75) | TSHRLOXL2KCNJ1KCNH2HRH3 | |
| SCHEMBL18913824 | 0.82 | TSHR (0.69) | TSHRLOXL2KCNJ1KCNH2HRH3 | |
| SCHEMBL30758863 | 0.82 | TSHR (0.69) | TSHRLOXL2KCNJ1KCNH2HRH3 | |
| SCHEMBL971348 | 0.82 | LOXL2 (0.61) | TSHRLOXL2KCNJ1KCNH2IDO1 | |
| SCHEMBL8094543 | 0.80 | POLB (0.68) | TSHRLOXL2KCNJ1KCNH2HRH3 | |
| SCHEMBL2588477 | 0.80 | TSHR (0.67) | TSHRLOXL2KCNJ1KCNH2HRH3 | |
| SCHEMBL250472 | 0.80 | TSHR (0.67) | TSHRLOXL2KCNJ1KCNH2HRH3 | |
| SCHEMBL3192905 | 0.78 | TSHR (0.64) | TSHRLOXL2KCNJ1KCNH2HRH3 | |
| SCHEMBL6245987 | 0.78 | TSHR (0.64) | TSHRLOXL2KCNJ1KCNH2HRH3 | |
| SCHEMBL1847096 | 0.78 | TSHR (0.64) | TSHRLOXL2KCNJ1KCNH2HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9671392-B2 | Multisensor array for detection of analytes or mixtures thereof in gas or liquid phase | DANMARKS TEKNISKE UNIVERSITET (DK) | 2017-06-06 | — | — | US | disclosed |
| US-20130096030-A1 | MULTISENSOR ARRAY FOR DETECTION OF ANALYTES OR MIXTURES THEREOF IN GAS OR LIQUID PHASE | SYDDANSK UNIVERSITET (DK) | 2013-04-18 | — | — | US | disclosed |
| EP-2553443-A1 | MULTISENSOR ARRAY FOR DETECTION OF ANALYTES OR MIXTURES THEREOF IN GAS OR LIQUID PHASE | Danmarks Tekniske Universitet (DK) | 2013-02-06 | — | — | EP | disclosed |
| WO-2011121077-A1 | MULTISENSOR ARRAY FOR DETECTION OF ANALYTES OR MIXTURES THEREOF IN GAS OR LIQUID PHASE | DANMARKS TEKNISKE UNIVERSITET (DK) | 2011-10-06 | — | — | WO | disclosed |
| US-7790735-B2 | Methanocarba cycloalkyl nucleoside analogues | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2010-09-07 | — | — | US | disclosed |
| US-20060270629-A1 | Methanocarba cycloalkyl nucleoside analogues | Govt of the U.S.A., represented by the Secretary, Dept of Health & Human Services (US) | 2006-11-30 | — | — | US | disclosed |
| EP-1252160-B1 | METHANOCARBA CYCLOALKYL NUCLEOSIDE ANALOGUES | US GOV HEALTH & HUMAN SERV (US) | 2006-08-16 | — | — | EP | disclosed |
| WO-2006083673-A2 | PYRIDINE DERIVATIVES USEFUL AS INHIBITORS OF C-JUN N-TERMINAL KINASES | ABBOTT LABORATORIES (US) | 2006-08-10 | — | — | WO | disclosed |
| US-7087589-B2 | Methanocarba cycloakyl nucleoside analogues | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2006-08-08 | — | — | US | disclosed |
| WO-2005030734-A1 | DIAMINOPYRIMIDINE DERIVATIVES AS SELECTIVE GROWTH HORMONE SECRECTGOGUE RECEPTOR (GHS-R) ANTAGONISTS | ABBOTT LABORATORIES (US) | 2005-04-07 | — | — | WO | disclosed |
| US-20030216412-A1 | Methanocarba cycloakyl nucleoside analogues | HEALTH AND HUMAN SERVICES, GOVERNMENT OF THE UNITED STATES OF AMERICA, THE, REPRESENTED BY THE SECRETARY, DEPARTMENT OF | 2003-11-20 | — | — | US | disclosed |
| EP-1252160-A1 | METHANOCARBA CYCLOALKYL NUCLEOSIDE ANALOGUES | THE UNITED STATES GOVERNMENT as represented by THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2002-10-30 | — | — | EP | disclosed |
| WO-2001051490-A1 | METHANOCARBA CYCLOALKYL NUCLEOSIDE ANALOGUES | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2001-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216412-A1 | Methanocarba cycloakyl nucleoside analogues | P2RY1, ADORA1, ADORA2A | TSHR 1912/4885LOXL2 4253/4885KCNJ1 154/4885 |
| US-20060270629-A1 | Methanocarba cycloalkyl nucleoside analogues | ADORA2A, ADORA1, ADORA2B | TSHR 1295/4885LOXL2 4374/4885KCNJ1 239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.